GLAB — Gemina Laboratories Cashflow Statement
0.000.00%
Last trade - 00:00- CA$57.43m
- CA$57.66m
Annual cashflow statement for Gemina Laboratories, fiscal year end - January 31st, CAD millions except per share, conversion factor applied.
2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | 2025 January 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.834 | -4.73 | -5.98 | -5.22 | -4.07 |
| Depreciation | |||||
| Non-Cash Items | 0.363 | 0.706 | 0.403 | 0.616 | 0.663 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.14 | 0.113 | 1.02 | 1.26 | 2 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -0.319 | -3.87 | -4.51 | -3.24 | -1.3 |
| Capital Expenditures | — | -0.01 | -0.08 | -0.041 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.014 | 0.018 | -0.425 | — | 0.018 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0.014 | 0.008 | -0.505 | -0.041 | 0.018 |
| Financing Cash Flow Items | 0.512 | 1.59 | 2.78 | -0.111 | -0.027 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.19 | 4.14 | 3.94 | 3.2 | 1.28 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.882 | 0.274 | -1.07 | -0.082 | -0 |